Last reviewed · How we verify

Decavac™ — Competitive Intelligence Brief

Decavac™ (Decavac™) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant toxoid vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant toxoid vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Decavac™ (Decavac™) — GlaxoSmithKline. Decavac is a recombinant vaccine designed to boost immune response against diphtheria, tetanus, and pertussis by providing booster immunization in adolescents and adults.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Decavac™ TARGET Decavac™ GlaxoSmithKline phase 3 Recombinant toxoid vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant toxoid vaccine class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Decavac™ — Competitive Intelligence Brief. https://druglandscape.com/ci/decavac. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: